Live News EARNINGS ARTICLE L impact Aug 05, 2026, 11:05 AM UTC

BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M Est

BioCryst Pharma (NASDAQ: BCRX ) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $666.201 million estimate.

BCRX

SquawkNews Newsroom

BioCryst Pharma (NASDAQ: BCRX ) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $666.201 million estimate.